CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...